Answers are grounded in this paper and cite their sources.
Multiple myeloma (MM) is a type of cancer that affects the plasma cells in your bone marrow. The severity of the disease can range from a less serious condition called monoclonal gammopathy of unknown significance (MGUS) to a more severe form called plasma cell leukemia (PCL). To ensure early treatment, the International Myeloma Working Group (IMWG) has updated the criteria for when to begin therapy. In this article, we discuss how MM progresses from MGUS to full-blown cancer at a molecular level. We also explain that because the disease is so complex, it cannot be treated with a single approach or by targeting one specific biomarker. While traditional biomarkers can be helpful in tracking the severity of the cancer, new biomarkers are being developed to create multi-target therapies that can be used at different stages of the disease.
No takes yet. Share an insight, caveat, or question.
Tahereh Kalantari (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: